Led · Seed · Aug 2021

pumpspotting offers a tech-enabled, community-centric lactation program that helps organizations implement comprehensive baby-feeding support and compliance with federal, state, and city laws. The platform is delivered as an employee benefit and as a commercial solution for guests, customers, fans, patients, and visitors. pumpspotting has served more than 70,000 parents since its founding, and the product emphasizes continuous community support and expert guidance for feeding journeys at work, home, and on-the-go. The company has expanded beyond workplace programs into retail and community partnerships and is launching pumpspotting Healthcare to serve health-care environments. pumpspotting positions its offering as a way for employers to attract, retain, and support parents while meeting new legal requirements such as the PUMP Act and the Pregnant Workers Fairness Act. Customers and partners cited in the article include DraftKings, Consigli Construction, Ally Logistics, the Portland Sea Dogs, and the Waukesha County Breastfeeding Coalition. pumpspotting provides software and services that support nursing, pumping, and breastfeeding parents, offering access to feeding experts, evidence-based content, and personalized encouragement. Its platform creates safe places to nurse and pump worldwide and connects a virtual community of parents 24×7. The company’s solutions are deployed by employers, retailers, universities and other partners. pumpspotting has supported a virtual community of more than 40,000 baby-feeding parents. The company raised $1.15M in seed funding and intends to use the proceeds to accelerate growth in the B2B channel. pumpspotting was founded in 2015 by CEO Amy VanHaren and is based in Kittery, Maine.

Participated · Seed · Jun 2019

NeuraLace Medical is a San Diego–based medical device startup founded in 2016 by Shiv Shukla that is developing Axon Therapy, a magnetic-field device intended to stimulate damaged nerves and relieve chronic pain. The device is designed to "trick" the brain by stimulating the nerve causing pain, offering a non-opioid treatment option. After seven years of work the company received a notice of allowance from the U.S. Patent and Trademark Office. NeuraLace is pursuing FDA 510(k) clearance and Shukla anticipated approval could come as soon as Q2 2020. The company raised $3.85 million in seed funding and plans to use roughly $1.1 million for hardware and software development, with the remainder allocated to its FDA application, clinical studies, and building units for commercial launch. With the new funding NeuraLace intends to add five contract software engineers and a full-time senior sales leader, and previous investors have doubled down. NeuraLace Medical develops non-opioid pain reduction treatments focused on chronic nerve pain. Its first commercial product, Axon Therapy, uses targeted pulsed magnetic fields to stimulate and reactivate damaged nerves to manage pain. The company intends to secure FDA 510(k) approval and to launch Axon Therapy using the funds. Once approved, Axon Therapy devices will be manufactured by D&K Engineering in San Diego. The company is led by founder and CEO Shiv Shukla. It raised $2M in funding to support regulatory clearance and product launch.